C4 Therapeutics, Inc. vs. Immunovant, Inc. Common Stock
Immunovant, Inc. Common Stock (IMVT) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| CCCC | IMVT | |
|---|---|---|
| Market Cap | $402.46 million | $8.21 billion |
| Revenue (TTM) | $34.86 million | — |
| Net Income (TTM) | $-103,801,000 | — |
IMVT leads on 1 of 1 size & scale factors.
Valuation
| CCCC | IMVT | |
|---|---|---|
| Price / Book | 1.72 | — |
| Price / Sales | 11.54 | — |
CCCC and IMVT split the valuation factors evenly.
Profitability
| CCCC | IMVT | |
|---|---|---|
| Net Margin | -297.76% | — |
| Return on Equity | -44.31% | — |
CCCC and IMVT split the profitability factors evenly.
Risk & Sentiment
| CCCC | IMVT | |
|---|---|---|
| Short Interest | 0.32% | 0.15% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: CCCC overview, CCCC financials, IMVT overview, IMVT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.